Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c

Opus Genetics, Inc. (NASDAQ: IRD) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.88 million versus the consensus estimate of $4.04 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• U.S. Bancorp stress capital buffer stays at 2.6% through 2027, plans to raise dividend 3.8%
• RBC Capital Starts Opus Genetics (IRD) at Outperform